Xeris Biopharma Holdings Inc (XERS)
3.36
+0.02
(+0.60%)
USD |
NASDAQ |
Nov 07, 16:00
3.41
+0.05
(+1.49%)
After-Hours: 06:36
Xeris Biopharma Holdings Revenue (TTM): 181.41M for June 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| June 30, 2024 | 181.41M |
| March 31, 2024 | 171.36M |
| December 31, 2023 | 163.91M |
| September 30, 2023 | 152.67M |
| June 30, 2023 | 134.07M |
| March 31, 2023 | 121.37M |
| December 31, 2022 | 110.25M |
| September 30, 2022 | 98.53M |
| June 30, 2022 | 79.87M |
| March 31, 2022 | 63.47M |
| December 31, 2021 | 49.59M |
| September 30, 2021 | 35.53M |
| June 30, 2021 | 33.87M |
| March 31, 2021 | 27.00M |
| Date | Value |
|---|---|
| December 31, 2020 | 20.48M |
| September 30, 2020 | 14.97M |
| June 30, 2020 | 5.88M |
| March 31, 2020 | 4.15M |
| December 31, 2019 | 2.722M |
| September 30, 2019 | 1.617M |
| June 30, 2019 | 1.886M |
| March 31, 2019 | 2.408M |
| December 31, 2018 | 2.423M |
| September 30, 2018 | 2.131M |
| June 30, 2018 | 1.719M |
| March 31, 2018 | 1.465M |
| December 31, 2017 | 1.556M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
2.722M
Minimum
Dec 2019
181.41M
Maximum
Jun 2024
77.43M
Average
63.47M
Median
Mar 2022
Revenue (TTM) Benchmarks
| Zoetis Inc | 9.152B |
| Zevra Therapeutics Inc | 23.99M |
| NovaBay Pharmaceuticals Inc | 12.02M |
| Palatin Technologies Inc | -- |
| iBio Inc | -- |